Reading TRAW? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TRAW free→Reading TRAW? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TRAW free→QuarterlyIQ Insights · TRAW
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. The information provided below in “
Other Events . On April 15, 2026, the Company issued a press release announcing that the Company had priced the offering of the Purchased Shares and Warrants. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. Forward Looking Statements Some of the statements in this report are forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Securities Exchange Act of…
Results of Operations and Financial Condition. The information provided below in “
in its entirety. Based in part upon the representations of the Investors in the Purchase Agreement, the issuances of the Securities in connection with the Private Placement are exempt from registration under the Securities Act pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder. Each of the Investors represented that they are an “accredited investor” as defined…
Entry into a Material Definitive Agreement PIPE Securities Purchase Agreement On April 15, 2026, Traws Pharma, Inc. (the “Company”) announced the pricing of an offering (the “Private Placement”) of an aggregate of (i) 5,982,919 shares (the “Purchased Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”) (or, in lieu of Purchased Shares, pre-funded warrants to purchase shares of Common Stock (“Pre-Funded Warrants”)), (ii) Series A warrants to initially purchase up…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 12, 2025, the Compensation Committee of the Board of Directors of Traws Pharma, Inc. (the “Company”) approved the grant of options to purchase shares of Company common stock (collectively, the “Options”) and restricted stock units (collectively, the “RSUs”) to the Company’s executive officers, as follows: 147,771 Options and 36,943 RSUs…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As described in
Results of Operations and Financial Condition. The information provided below in “
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 12, 2025, the Compensation Committee of the Board of Directors of Traws Pharma, Inc. (the “Company”) approved the grant of options to purchase shares of Company common stock (collectively, the “Options”) to the Company’s executive officers, as follows: 64,839 Options to Iain Dukes, the Company’s Chief Executive Officer; 32,406 Options to…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Independent Director On October 1, 2025, upon recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (“Board”) of Traws Pharma, Inc. (the “Company”), the Board appointed John Leaman, MD as an independent director, with a term expiring at the Company’s 2025 annual meeting of stockholders. Dr. Lea…
Completion of Acquisition or Disposition of Assets. The information in
Entry into a Material Definitive Agreement. On September 9, 2025, Traws Pharma, Inc. (the “Company”) and Virom, Inc. (“Viriom”) entered into an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company purchased certain assets (the “Purchased Assets”) from Viriom in exchange for $2,350,000 in cash (the “Purchase Price”), which was paid in full to Virom on September 9, 2025. The Purchased Assets include certain intellectual property and other assets related to a pyrrol…
Results of Operations and Financial Condition. The information provided below in “
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers. Resignation of Nora Brennan On July 2, 2025, Nora Brennan notified Traws Pharma, Inc. (the Company”) of her decision to resign from her role as Interim Chief Financial Officer of the Company, effective as of July 5, 2025 (the “Termination Date”), which is the final day of the interim period contemplated by that offer letter entered into by and…
Results of Operations and Financial Condition. The information provided below in “
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed in that Current Report on Form 8-K filed by Traws Pharma, Inc. (the “Company”) with the Securities and Exhange Commission on March 28, 2025, Iain Dukes was appointed as the Company’s Interim Chief Executive Officer, effective as of the close of business on March 31, 2025. On April 16, 2025, the Company and Dr. Dukes entered…
Results of Operations and Financial Condition. The information provided below in “
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers. Retirement of Werner Cautreels On March 28, 2025, Werner Cautreels notified Traws Pharma, Inc. (the Company”) of his decision to retire and resign from his role as Chief Executive Officer of the Company, effective as of the close of business on the day that the Company files its Annual Report on Form 10-K for its 2024 fiscal year with the Secur…
Entry into a Material Definitive Agreement. On March 10, 2025, Traws Pharma, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “ATM Agreement”) with Citizens JMP Securities, LLC (“Citizens”), pursuant to which the Company may offer and sell shares of its common stock, having aggregate sales price of up to $50,000,000 (subject to certain limitations set forth in the ATM Agreement), from time to time, to or through Citizens, acting as sales agent and/or principal. Sales…
Entry into a Material Definitive Agreement. As previously disclosed in that Current Report on Form 8-K filed by Traws Pharma, Inc. (the “Company”) with the Securities and Exchange Commission on December 31, 2024, on December 29, 2024, the Company entered into a Securities Purchase Agreement with certain purchasers named therein (the “Purchasers”), pursuant to which, on December 31, 2024, the Company sold and issued to the Purchasers an aggregate of (i) 3,630,205 Class A Units (“Class A Units”…
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers. Resignation of Mark Guerin On February 5, 2025 (the “Termination Date”), Mark Guerin resigned from his position as the Chief Financial Officer of Traws Pharma, Inc. (the “Company”), effective immediately. As a result of Mr. Guerin’s resignation, that employment agreement entered into by and between the Company and Mr. Guerin, dated July 1, 2015…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.